179 related articles for article (PubMed ID: 28948379)
1. Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis.
Zhang K; Zheng Y; Jia J; Ding J; Wu Z
Clin Rheumatol; 2018 Jan; 37(1):5-11. PubMed ID: 28948379
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: A systematic review and meta-analysis of observational studies.
Yuan Q; Xing X; Lu Z; Li X
Semin Arthritis Rheum; 2020 Oct; 50(5):1022-1039. PubMed ID: 32911280
[TBL] [Abstract][Full Text] [Related]
3. Antiphospholipid antibodies and osteonecrosis in systemic lupus erythematosus: a meta-analysis.
Qijiao W; Meng Z; Jianwen L; Shengli Z; Fei G; He L; Zhihan C
Expert Rev Clin Immunol; 2021 Aug; 17(8):923-932. PubMed ID: 33956556
[No Abstract] [Full Text] [Related]
4. Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: A systematic review and meta-analysis.
Guan SY; Cai HY; Wang P; Lv TT; Liu LN; Mao YM; Zhao CN; Wu Q; Dan YL; Sam NB; Wang DG; Pan HF
Int J Rheum Dis; 2019 Oct; 22(10):1803-1813. PubMed ID: 31468723
[TBL] [Abstract][Full Text] [Related]
5. Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study.
Long Y; Zhang S; Zhao J; You H; Zhang L; Li J; Leng X; Wang Q; Tian X; Li M; Zeng X
Lupus; 2021 Aug; 30(9):1459-1468. PubMed ID: 34082592
[TBL] [Abstract][Full Text] [Related]
6. The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis.
Zhu KK; Xu WD; Pan HF; Zhang M; Ni J; Ge FY; Ye DQ
Inflammation; 2014 Oct; 37(5):1852-64. PubMed ID: 24862229
[TBL] [Abstract][Full Text] [Related]
7. Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus.
Tse SM; Mok CC
Lupus; 2017 Jun; 26(7):715-722. PubMed ID: 27831540
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors.
Gladman DD; Dhillon N; Su J; Urowitz MB
Lupus; 2018 Jan; 27(1):76-81. PubMed ID: 28530464
[TBL] [Abstract][Full Text] [Related]
9. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management.
Zheng Y; Zheng Z; Zhang K; Zhu P
Autoimmun Rev; 2022 Feb; 21(2):102992. PubMed ID: 34793961
[TBL] [Abstract][Full Text] [Related]
11. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus.
Fialho SC; Bonfá E; Vitule LF; D'Amico E; Caparbo V; Gualandro S; Pereira RM
Lupus; 2007; 16(4):239-44. PubMed ID: 17439929
[TBL] [Abstract][Full Text] [Related]
12. Relationship between osteonecrosis and antiphospholipid antibodies in patients with systemic lupus erythematosus: a systematic review protocol.
Wei Q; Zhou M; Liu J; Zhang S; Gao F; Lin H; Chen Z
BMJ Open; 2021 Jul; 11(7):e046163. PubMed ID: 34301653
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis comparing complications following total hip arthroplasty for systemic lupus erythematosus versus for non-systemic lupus erythematosus.
Huang Y; Guan D; Li Y; Li J; Zeng Y
J Orthop Surg Res; 2022 Apr; 17(1):235. PubMed ID: 35414010
[TBL] [Abstract][Full Text] [Related]
14. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis.
Fatoye F; Gebrye T; Mbada C
Rheumatol Int; 2022 Dec; 42(12):2097-2107. PubMed ID: 36006459
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and risk factors in 118 patients with systemic lupus erythematosus and osteonecrosis].
Li NN; Chen YJ; Leng XM; Zhang W; Tian XP; Zhao Y; Zeng XF
Zhonghua Nei Ke Za Zhi; 2021 Aug; 60(8):744-750. PubMed ID: 34304451
[No Abstract] [Full Text] [Related]
16. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of mesenchymal stem cells on systemic lupus erythematosus:a meta-analysis].
Liu S; Guo YL; Yang JY; Wang W; Xu J
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 50(6):1014-1021. PubMed ID: 30562774
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.
Joo YB; Sung YK; Shim JS; Kim JH; Lee EK; Lee HS; Bae SC
Rheumatol Int; 2015 May; 35(5):879-86. PubMed ID: 25300729
[TBL] [Abstract][Full Text] [Related]
19. Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.
Puapatanakul P; Chansritrakul S; Susantitaphong P; Ueaphongsukkit T; Eiam-Ong S; Praditpornsilpa K; Kittanamongkolchai W; Avihingsanon Y
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597273
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic osteonecrosis of the hip and knee in patients with systemic lupus erythematosus: Prevalence, pattern, and comparison of natural course.
Ersin M; Demirel M; Ekinci M; Mert L; Çetin Ç; Artım Esen B; İnanç M; Kılıçoğlu ÖI
Lupus; 2021 Sep; 30(10):1603-1608. PubMed ID: 34259056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
